Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment

Cancer Research

Volumn 76, Issue 8, 2016, Pages 2125-2136

  Stiff, Andrew ^a,b   Trikha, Prashant ^c   Wesolowski, Robert ^b   Kendra, Kari ^b   Hsu, Vincent ^c   Uppati, Sarvani ^c   McMichael, Elizabeth ^b   Duggan, Megan ^b   Campbell, Amanda ^a,b   Keller, Karen ^c   Landi, Ian ^c   Zhong, Yiming ^c   Dubovsky, Jason ^c   Howard, John Harrison ^d   Yu, Lianbo ^b   Harrington, Bonnie ^c   Old, Matthew ^b   Reiff, Sean ^a,b   Mace, Thomas ^b   Tridandapani, Susheela ^b,d   Muthusamy, Natarajan ^c   Caligiuri, Michael A ^c   Byrd, John C ^c   Carson, William E ^c   more..

^a Medical Scientist Program   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BRUTON TYROSINE KINASE; IBRUTINIB; INDOLEAMINE 2,3 DIOXYGENASE; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CYTOKINE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CANCER; BREAST TUMOR; CELL MIGRATION; CONTROLLED STUDY; DEPLETION; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; DRUG SCREENING; ENZYMOLOGY; IMMUNOTHERAPY; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971009622     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1490     Document Type: Article

References (49)

1. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-84.
2. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in cerbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-45.
3. Gabrilovich DI,Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
4. Gabrilovich DI,Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
5. Trikha P,Carson WE3rd. Signaling pathways involved inMDSCregulation. Biochim Biophys Acta 2014;1846:55-65.
6. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: moremechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59:1593-600.
7. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells throughmembrane-bound TGFbeta 1. J Immunol 2009;182:240-9.
8. Jitschin R, BraunM, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, et al. CLLcells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014;124:750-60.
9. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011;71:5101-10.
10. Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, et al. Patients with pancreatic adenocarcinoma exhibit elevated levels ofmyeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother 2015;64:149-59.
11. Wang L, Chang EW, Wong SC, Ong SM, Chong DQ, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013; 190:794-804.
12. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30.
13. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59.
14. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702.
15. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Aminobiphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-46.
16. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013;21:887-94.
17. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H,Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Translat Med 2014;6:237ra67.
18. Wesolowski R, Markowitz J, Carson WE3rd. Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013;1:10.
19. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014;123: 3286-95.
20. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
21. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:1278-9.
22. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
23. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:2539-49.
24. Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 2011;117:1329-39.
25. Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, et al. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. Blood 2010;115:3118-27.
26. Honda F, Kano H, Kanegane H, Nonoyama S, Kim ES, Lee SK, et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 2012;13:369-78.
27. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011;13: R115.
28. Lee KG, Xu S, Kang ZH, Huo J, Huang M, Liu D, et al. Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci U S A 2012;109:5791-6.
29. Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011;12:416-24.
30. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 2009;85: 996-1004.
31. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 2000;165:6723-30.
32. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014;123:1207-13.
33. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science (New York, NY) 1993;261:358-61.
34. Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, et al. Myeloidderived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 2013;73:672-82.
35. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-4.
36. Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006;176:3635-41.
37. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011;71:7463-70.
38. Ni Gabhann J, Hams E, Smith S, Wynne C, Byrne JC, Brennan K, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PloS One 2014;9:e85834.
39. Kawakami Y, Inagaki N, Salek-Ardakani S, Kitaura J, Tanaka H,Nagao K, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci U S A 2006;103:153-8.
40. Strauss L, Sangaletti S, Consonni Francesca M, Szebeni G, Morlacchi S, Totaro Maria G, et al. RORC1 regulates tumor-promoting "emergency" granulo-monocytopoiesis. Cancer Cell 28:253-69.
41. Ansell SM. Two targets for the price of one. Blood 2013;122;2529-31 p.
42. Qin H, Lerman B, Sakamaki I,Wei G, Cha SC, Rao SS, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2014;20:676-81.
43. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111:11774-9.
44. Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q, et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol 2015;294:54-59.
45. Mace TA, Ameen Z, Collins A, Wojcik S,Mair M, Young GS, et al. Pancreatic cancer-associated stellate cells promote differentiation ofmyeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013;73: 3007-18.
46. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinibmediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
47. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011;11:856-61.
48. Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 2015;112:E966-72.
49. OhK, Lee OY, Shon SY,NamO, Ryu PM, SeoMW,et al. Amutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res 2013;15:R79.